MarketPulse

weight management

5 articles
BenzingaBenzinga··Prnewswire

DarioHealth to Report Q1 2026 Results; CEO to Detail Digital Health Strategy

DarioHealth reports Q1 2026 earnings on May 13, 2026, with CEO, President, and CFO discussing financial results and strategic initiatives via conference call.
DRIOearnings announcementconference call
GlobeNewswire Inc.GlobeNewswire Inc.··Globe Newswire

Arla Foods Targets GLP-1 Market With Specialized Nutrition Products

Arla Foods Ingredients launches specialized high-protein nutrition products for GLP-1 medication users, debuting at Vitafoods Europe 2026.
NVZMYGLP-1 medicationsprobiotics
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Pharma Giants Poised for Growth: Lilly, Vertex, Pfizer Lead March 2026 Rally

Eli Lilly dominates weight management, Vertex controls cystic fibrosis, and Pfizer offers undervalued shares with 6.3% dividend yield.
PFELLYVRTXdividend yieldcystic fibrosis
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Zealand Pharma's Petrelintide Shows Promise in Obesity Drug Race

Zealand Pharma reports positive Phase 2 data for petrelintide, achieving 10.7% weight loss versus 1.7% placebo with favorable safety profile.
RHHBYZLDPYobesityweight management
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Therapeutics Market Poised to Exceed $33B by 2030 on Formulation Innovation

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.
PFELLYNVOAZNpersonalized medicinediabetes treatment